Press Release: Novonesis delivered 8% organic sales growth in the first nine months of 2025

Dow Jones11-06

Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards.

COPENHAGEN, Denmark -- November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%.

Ester Baiget, President & CEO:

"I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong across all sales areas and in emerging and developed markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quarter, we indicate mid-single-digit organic sales growth for the fourth quarter and lift the bottom end of the range now expecting 7-8% for the full year. We continue to execute on our strategic priorities, positioning us firmly to deliver on our 2030 targets."

Highlights of our 9M results:

- Strong broad-based organic sales growth of 8% (Q3: 6%), including the negative impact of exiting certain countries of 1 percentage point (Q3: 2 percentage points). Price contributed by 1 percentage point (Q3: 1 percentage point).

- Food & Health at 9% organic sales growth (Q3: 6%) including the negative impact of exiting certain countries of 2 percentage points (Q3: 5 percentage points). Planetary Health at 8% organic sales growth (Q3: 6%).

- Emerging Markets at 12% organic sales growth (Q3: 10%); Developed Markets at 6% organic sales growth (Q3: 4%).

- Adjusted EBITDA margin at 37.3% (Q3: 37.1%), up by 130 bps (Q3: down by 30 bps). including significant currency headwinds. Adjusted net profit increased by 22% (Q3: 19%).

- NIBD/EBITDA at 2.0x, and free cash flow before acquisitions at EUR 668.4 million (Q3: EUR 361.3 million).

2025 outlook: Organic sales growth is now expected between 7-8% (previously 6-8%) including an indication of mid-single-digit growth in Q4 following favorable timing in Q3. Excluding the exit from certain countries, organic sales growth for the year is expected at 8-9% (previously 7-9%). The adjusted EBITDA margin is expected at the lower end of the 37-38% range, including significant currency headwinds.

Media relations

Magnus Højberg Mernild

Senior Media Relation Manager

media-relations@novozymes.com

+45 51 71 78 30

Tobias Cornelius Bjorklund

Head of Investor Relations

tobb@novonesis.com

Attachment 

   -- 2025_46_9M_Interim_report

(END) Dow Jones Newswires

November 06, 2025 05:12 ET (10:12 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment